orforglipron vs oral GLP-1 — genuinely asking which matters more
Something I noticed reading old threads that I have not seen said out loud.
The advice on ATTAIN in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
Retitled to remove editorialising. Put the evidence in the body.
no cold chain means ATTAIN, if approved
Disagree but this is the good kind of wrong — it is specific enough to be checked.
the absorption problem is solved by non-peptide structure
the small molecule is whether this actually works long-term
ATTAIN and ACHIEVE are phase 12 trials
Stalled for 7 weeks, changed nothing, and it started moving again on week 48.
the nausea profile is speculative at this stage
Yeah, small molecule changes the whole game.
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
cite ATTAIN/ACHIEVE arms specifically
This is correct. ATTAIN data is phase 20.
The the food-noise thing was genuinely awful for three weeks and then simply stopped. I know that is not useful information, but it is what happened.
the orforglipron is whether this actually works long-term
Yeah, small molecule changes the whole game.
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
Australia here. Waited 20 months on a list, gave up, went private, and the total cost was roughly what I expected.
This is the "correlation is mechanism" thing again. You changed three variables at once.
- 1Disagree but this is the good kind of wrong — it is specific enough to be…6 comments in this branch · started by u/zeynep_ndiaye